Consort Medical plc (the ‘Company’) is pleased to announce the appointment of Chris Brinsmead CBE as a Non-executive Director and Chairman designate. Chris will join the Board on 7 February 2019 and will succeed Dr. Peter Fellner as Chairman, on 24 April 2019. Peter will step down from the board on the same date; his intention to step down was announced on 14 June 2018.
Chris is currently the Senior Independent Non-executive Director of UDG Healthcare plc and a non-executive director of Collagen Solutions plc and The Wesleyan Assurance Society. In addition, Chris is a member of council at Imperial College London.
Chris has worked in the global pharmaceutical sector for over thirty years, and has significant international, operational and strategic expertise. He was formerly the Chairman of AstraZeneca Pharmaceuticals UK, President of AstraZeneca UK and Ireland and President of the Association of the British Pharmaceutical Industry (ABPI). He has previously held Board positions at Domino Printing Sciences plc (2008-2016), Cambian Group plc (2014-2017) and Proteus Digital Health Inc (2010-2015).
Commenting on the appointment, Senior Independent Director Dr. William Jenkins said on behalf of the Board, “We are delighted to welcome Chris to the Group. He brings with him a strong track record, a wealth of pharma experience and is an established senior board member with significant international, operational and strategic expertise”. He added “I would like to thank Peter for his very significant contribution to Consort Medical’s success during his tenure. Peter has provided expert guidance and has supported the Board and management team in the delivery of our strategy, leaving the business in a strong operational and financial position.”
Commenting on his appointment, Chris Brinsmead said: “I am thoroughly looking forward to joining the Board of Consort Medical plc and building on its leading position as a global contract development and manufacturing organisation.”
About Consort Medical plc
Consort Medical plc is a leading one-stop developer and manufacturer of drugs and premium drug delivery devices. We partner with pharmaceutical businesses in providing innovative life improving treatments to patients across the world through two integrated activities:
The design, development and manufacture of high performance medical devices for inhaled, injectable, nasal and ocular drug delivery, as well as point of care diagnostics products.
The development, formulation and manufacture of active pharmaceutical ingredients (APIs) and finished dose drugs to the highest quality standards.
We employ over 2,000 people globally and are committed to investing in patient, clinician and customer driven innovation to create new treatments.